Race Oncology (ASX:RAC) Announces Safe Dosing of First Patient in Phase 1 RC220 Trial
Clinical Trial Progress
Race Oncology successfully dosed the first patient with RC220 in its Phase 1 clinical trial for advanced solid tumours. The patient was treated at Southside Cancer Care Centre in Miranda, NSW, with no adverse events reported.
Trial Details
The Phase 1 trial aims to determine the safety, tolerability, and pharmacokinetics of RC220, alongside the maximum tolerated combined dose with doxorubicin. Up to 33 patients will be recruited across Australia, Hong Kong, and South Korea in Stage 1. The trial employs a Bayesian design for greater flexibility and speed.
Executive Comments
CEO Dr Daniel Tillett stated, “The safe dosing of the first patient in our solid tumour trial is a major milestone for Race Oncology and the beginning of an important program to assess the safety, tolerability and therapeutic potential of RC220. We are grateful to all the patients, investigators, and clinical teams who have made this trial possible. I would also like to thank our shareholders for their strong and loyal support that has enabled us to bring RC220 to patients in the clinic.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
